Abstract
We covalently linked doxorubicin with a peptide that is hydrolyzable by prostate-specific antigen. In the presence of prostate tumor cells secreting prostate-specific antigen, the peptide moiety of this conjugate, L-377,202, was hydrolyzed, resulting in the release of leucine-doxorubicin and doxorubicin, which are both very cytotoxic to cancer cells. However, L-377,202 was much less cytotoxic than conventional doxorubicin to cells in culture that do not secrete prostate-specific antigen. L-377,202 was approximately 15 times more effective than was conventional doxorubicin at inhibiting the growth of human prostate cancer tumors in nude mice when both drugs were used at their maximally tolerated doses. Nude mice inoculated with human prostate tumor cells secreting prostate-specific antigen showed considerable reductions in tumor burden with minimal total body weight loss when treated with L-377,202. This improvement in therapeutic index correlated with the selective localization of leucine–doxorubicin and free doxorubicin in tissues secreting prostate-specific antigen after exposure to L-377,202.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Husain, M.H., Blumenstein, B., Eisenberger, M. & Crawford, E.D. Southwest Oncology Group studies in hormone-refractory prostate cancer. Semin. Oncol. 23, 24–27 (1996).
Lilja, H. A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. J. Clin. Invest. 76, 1899–1903 (1985).
Akiyama, K., Nakamura, T., Iwanaza, S. & Hara, M. The chymotrypsin-like activity of human prostate specific antigen, g-seminoprotein. FEBS LETTERS 235, 168–172 (1987)]
Yu, H. et al. Ectopic production of prostate specific antigen by a breast tumor metastatic to the ovary. J. Clin. Lab. Anal. 8, 251–253 (1994)
Diamandis, E., Yu, H. & Sutherland, D.J.A. Detection of prostate specific antigen immunoreactivity in breast tumors. Breast Cancer Res. Tr. 32, 301–310 (1994).
Yu, H., Diamandis, E. & Sutherland, D.J.A. Immunoreactive prostate specific antigen levels in female and male breast tumors and its association with steroid hormone receptors and patient age. Clin. Biochem. 27, 75–79 (1994).
Levesque, M., Yu, H., D'Costa, M. & Diamandis, E. . Prostate specific antigen expression by various tumors. J. Clin. Lab. Anal. 9, 123–128 (1995).
Diamandis, E. New diagnostic applications and physiological functions of prostate specific antigen. Scand. J. Clin. Lab. Invest. 55, 105–112 (1995).
Catalona, W.J., Smith, D.S., Ratliff, T.L., Dodds, K. M., Coplen, d.e., Yuan, J. J., Petros, J.A., & Andriole, G.L., Measurement of Prostrate-specific antigen in serum as a screning test for Prostrae cancer. New England Journal of Medicine 324, 1156(1991).]
Christensson, A., Laurell, C. & Lilja. H. . Enzymatic activity of prostate specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur. J. Biochem. 194, 755–763 (1990).
Leinonen, J., Zhang. W. & Stenman, U. . Complex formation between psa isoenzymes and protease inhibitors. J. Urol. 155, 1099–1103 (1996).
Otto, A., Bar, J. & Birkenmeier, G. Prostate specific antigen forms complexes with human a2-macroglobulin and binds to the a2-macroglobulin receptor/ldl receptor-related protein. J. Urol. 159, 297–303 (1998).
Christensson, A. & Lilja, H. Complex formation between protein C inhibitor and prostate specific antigen in vitro and in human semen. Eur. J. Biochem. 220, 45–53 (1994).
Wainstein, M.A. et al. CWR22: androgen-dependent xenograft model derived from a primary prostatic carcinoma. Cancer Res. 54, 6049–6052 (1994).
Denmeade, S.R. et al. Enzymatic activation of a doxorubicin-peptide prodrug by prostate specific antigen. Cancer Res. 58, 2537–2540 (1998).
Tan, C. et al. Daunorubicin, an antitumoral antibiotic in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia. Cancer 20, 333–353 (1967).
Macrez, C. et al. Accidents cardiaques observes en cours des traitment par rubidomycine. Pathol. Biol. 15, 949–953 (1967).
Johansen, P.B. . Doxorubicin pharmacokinetics after intravenous and intraperitoneal administration in the nude mouse. Cancer Chemother. Pharmacol. 5, 267–270 (1981).
Westfall, P.H. & Young, S.S. in Resampling Based Multiple Testing (John Wiley & Sons, New York, 1993). pp 112–145
SAS Institute. SAS/STAT Software: Changes and Enhancements Through Release 6.11. (SAS Institute, Cary, North Carolina, 1996).
Dunnett, C.W. A multiple comparison procedure for comparing several treatments with a control. J. American Statistical Assoc. 50, 1096–1121 (1955).
SAS Institute. SAS/STAT User's Guide Version 6, 4th edn. Vol. 2 (SAS Institute, Cary, North Carolina, 1990). pp 891–996
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
DeFeo-Jones, D., Garsky, V., Wong, B. et al. A peptide–doxorubicin 'prodrug' activated by prostate-specific antigen selectively kills prostate tumor cells positive for prostate-specific antigen in vivo. Nat Med 6, 1248–1252 (2000). https://doi.org/10.1038/81351
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/81351
This article is cited by
-
Synthesis and evaluation of new 4-peptidamido-2-fluorobenzyl phosphoramide mustard conjugates as prodrugs activated by prostate-specific antigen
Medicinal Chemistry Research (2020)
-
Synthesis and evaluation of new peptide-linked doxorubicin conjugates as prodrugs activated by prostate-specific antigen
Medicinal Chemistry Research (2020)
-
Anticancer polymers designed for killing dormant prostate cancer cells
Scientific Reports (2019)
-
Beyond the biomarker role: prostate-specific antigen (PSA) in the prostate cancer microenvironment
Cancer and Metastasis Reviews (2019)
-
Roles of the first-generation claudin binder, Clostridium perfringens enterotoxin, in the diagnosis and claudin-targeted treatment of epithelium-derived cancers
Pflügers Archiv - European Journal of Physiology (2017)